地诺单抗与唑来膦酸用于多发性骨髓瘤的骨靶向治疗：尚未解决的问题有哪些？ - Suppr | 超能文献

Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?

作者信息

Chakraborty Rajshekhar, Majhail Navneet S, Anwer Faiz

机构信息

Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio.

Multiple Myeloma Program, Cleveland Clinic, Cleveland, Ohio.

出版信息

JAMA Oncol. 2019 Aug 1;5(8):1095-1096. doi: 10.1001/jamaoncol.2019.1598.

DOI:10.1001/jamaoncol.2019.1598

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?地诺单抗与唑来膦酸用于多发性骨髓瘤的骨靶向治疗：尚未解决的问题有哪些？

JAMA Oncol. 2019 Aug 1;5(8):1095-1096. doi: 10.1001/jamaoncol.2019.1598.

2

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.地舒单抗对比唑来膦酸在初诊多发性骨髓瘤骨病治疗中的应用：一项国际性、双盲、双模拟、随机、对照、3 期研究。

Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9.

3

Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.地诺单抗与唑来膦酸对骨转移癌患者钙水平的影响：一项回顾性队列研究。

J Oncol Pharm Pract. 2019 Dec;25(8):1846-1852. doi: 10.1177/1078155218820927. Epub 2019 Jan 7.

4

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.美国地诺单抗预防多发性骨髓瘤患者骨相关事件的成本效益分析。

J Med Econ. 2018 May;21(5):525-536. doi: 10.1080/13696998.2018.1445634. Epub 2018 Mar 5.

5

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.在一项随机3期试验中评估接受地诺单抗或唑来膦酸治疗的多发性骨髓瘤患者亚组的结果。

Blood Cancer J. 2016 Jan 8;6(1):e378. doi: 10.1038/bcj.2015.96.

6

The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.地舒单抗在预防转移性骨病癌症患者恶性高钙血症中的作用。

Eur J Cancer. 2015 Jul;51(11):1467-75. doi: 10.1016/j.ejca.2015.04.017. Epub 2015 May 11.

7

Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.地舒单抗与唑来膦酸预防脆弱性癌症患者骨骼相关事件的比较：一项随机对照试验的荟萃分析。

Clin Ther. 2020 Aug;42(8):1494-1507.e1. doi: 10.1016/j.clinthera.2020.05.019. Epub 2020 Jul 24.

8

[Management of bone disease in myeloma patients: zoledronic acid or denosumab?].[骨髓瘤患者骨病的管理：唑来膦酸还是地诺单抗？]

Rinsho Ketsueki. 2015 Aug;56(8):997-1004. doi: 10.11406/rinketsu.56.997.

9

Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.晚期乳腺癌的骨相关并发症和生活质量：地舒单抗对比唑来膦酸的随机 III 期临床试验结果。

Clin Cancer Res. 2012 Sep 1;18(17):4841-9. doi: 10.1158/1078-0432.CCR-11-3310. Epub 2012 Aug 14.

10

[Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab].[从唑来膦酸转换为地诺单抗的多发性骨髓瘤患者的骨代谢标志物]

Rinsho Ketsueki. 2014 Nov;55(11):2271-6.

引用本文的文献

1

Treatment and disease-related complications in multiple myeloma: Implications for survivorship.多发性骨髓瘤的治疗和与疾病相关的并发症：对生存状况的影响。

Am J Hematol. 2020 Jun;95(6):672-690. doi: 10.1002/ajh.25764. Epub 2020 Mar 13.

2

Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma.多发性骨髓瘤的 Medicare 受益人群中使用骨修饰药物的情况。

JAMA Oncol. 2020 Feb 1;6(2):296-298. doi: 10.1001/jamaoncol.2019.5426.